Mirum Pharmaceuticals, Inc. MIRM Licensing Arrangements
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedRoyaltiesCurrent.
The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mirum Pharmaceuticals, Inc.'s licensing arrangements.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mirum Pharmaceuticals, Inc.'s licensing arrangements?
- Mirum Pharmaceuticals, Inc. (MIRM) reported licensing arrangements of $15.22M in Q1 2026.
- How has Mirum Pharmaceuticals, Inc.'s licensing arrangements changed year-over-year?
- Mirum Pharmaceuticals, Inc.'s licensing arrangements increased by 50.9% year-over-year, from $10.09M to $15.22M.
- What is the long-term trend for Mirum Pharmaceuticals, Inc.'s licensing arrangements?
- Over 2 years (2023 to 2025), Mirum Pharmaceuticals, Inc.'s licensing arrangements has grown at a 55.3% compound annual growth rate (CAGR), from $6.72M to $16.21M.